This collaboration reinforces Aptar’s position as a trusted partner in the evolving landscape of nasal vaccine delivery ...

The clinical trial ecosystem is entering a phase of consolidation and reinvention driven by the collapse of boundaries between functions, data, and even companies themselves.

TORONTO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and ...

Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic ...

Frontage Laboratories, Inc., a leading contract development and manufacturing organization (CDMO) announced that its new ...

SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or ...

Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.

Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for ...

PRINCETON, N.J., April 21, 2023 /PRNewswire/ -- Oblato, Inc. (the Company), a subsidiary company of HLB Therapeutics in Korea, has announced today the first enrollment for recurrent high-grade glioma ...

- Using Ascletis' proprietary Ultra-Long-Acting Platform technology, co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly ...

Depomed, Inc. (NASDAQ: DEPO) announced today that it has received another $500,000 milestone payment after the first formulation that is being developed under its worldwide license agreement with ...